A minimally invasive technique called liquid biopsy (LB) seeks to identify circulating tumor-derived elements in bodily fluids. It provides an alternative to current cancer screening methods that use tissue biopsies for the confirmation of diagnosis. This essay looks at the degree to which the governance, legislative, and regulatory frameworks enable the integration of LB into healthcare systems and offers suggestions for how to make things better.
HTML PDFShare this article
